#TSW The MEDIATE Initiative (Mitigating Eczema Disinformation and Intervening with AI Technology Education) is a project focused on developing an autonomous digital intervention for self-diagnosed Topical Steroid Withdrawal (TSW). The Clinical Challenge The dermatological community is increasingly facing the consequences of poor treatment adherence aggravated by “corticophobia”. This challenge has been exacerbated over the past […]
Read More
Standardizing the approach without standardizing the patient The rapid expansion of effective systemic treatments has made Treat-to-Target a natural next step in atopic dermatitis. Once substantial improvement becomes achievable for many patients, it is no longer sufficient to ask whether a treatment works. We must determine what level of control should be reached, when it […]
Read More
Eczema herpeticum after topical JAK inhibition:Eczema Herpeticum Following Topical Ruxolitinib Use: A Report of Two CasesZhang K et al. Annals of Allergy, Asthma & Immunology. 2026.➜ DOI: 10.1016/j.anai.2026.06.016Why it matters:Eczema herpeticum is one of the most clinically important infectious complications of AD. These two cases are noteworthy because they occurred following treatment with topical ruxolitinib, reminding [...] Read More
#RAJKAMedal Rajka medal and prize: the winner among 4 excellent applicants originating from Indonesia, Ireland, Japan and Madagascar, is Dr Ge PENG, MD, PhD, Associate Professor at the Atopy Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan. Brief description of the research project Atopic dermatitis is a common long-term skin condition that can […]
Read More
We are pleased to announce the third edition of the J-DAC conference, dedicated to exploring the “One Health” approach to atopic dermatitis. This upcoming edition will focus specifically on one of the most significant recent therapeutic advancements in the field: Janus kinase inhibitors (JAKi). The program offers a unique opportunity to bridge human and veterinary […]
Read More
S. aureus and Eczema Herpeticum: A Laboratory Paradox, a Bedside Emergency Eczema herpeticum, or Kaposi-Juliusberg syndrome caused by HSV-1, is one of the situations in atopic dermatitis where clinical hesitation can be dangerous. Dermatologists who have seen severe cases remember the picture well: sudden painful monomorphic vesicles or punched-out erosions on eczematous skin, fever, facial […]
Read More
Can inflamed AD skin become a gateway for topical biologics?➜ DOI: 10.34133/bmr.0368Why it matters:A thermosensitive hyaluronic acid/Pluronic hydrogel delivered mesenchymal stromal cell-derived extracellular vesicles through AD-like lesional skin in mice, improving dermatitis scores, epidermal thickening, mast-cell infiltration, cytokine expression, barrier markers, and oxidative stress.Context and caution:The most intriguing point is that damaged AD skin allowed EV [...] Read More
Dr. Roberto TAKAOKA’s visit to Manaus launches a vital new support network while opening doors to unique environmental research on atopic dermatitis. Last month, Dr Roberto TAKAOKA, Vice-President of ISAD, visited Manaus in the heart of Brazil’s Amazon region as part of a project by the Brazilian Atopic Dermatitis Association (AADA) to establish new support […]
Read More
The success of the second call for the ISAD-GADA Fellowship was highlighted, with seven applicants from six different countries (Ethiopia, Ghana, Lebanon, Madagascar, Malaysia and Nepal). A heartfelt thank you to everyone who applied. We were genuinely encouraged by the volume and quality of submissions we received. We are delighted to inform that Dr Naina […]
Read More
From “Response” to “Reassurance” Topical corticosteroids (TCS) remain the cornerstone of atopic dermatitis (AD) management worldwide. Yet, despite decades of clinical use, a paradox persists: while clinicians rely on TCS as first-line therapy, many patients remain uncertain, and sometimes fearful, about how to use them safely over time. This tension is increasingly visible in discussions […]
Read More